Bullfrog AI (BFRG) vs Phio Pharmaceuticals (PHIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Bullfrog AI (BFRG) has outperformed Phio Pharmaceuticals (PHIO) over the past year, losing 54.8% versus a loss of 58.5%. Bullfrog AI is the larger company by market cap ($12.0 million vs $11.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BFRG | PHIO |
|---|---|---|
| Share price | $0.646 | $0.9788 |
| Market cap | $11.98M | $11.37M |
| 1-day change | -6.70% | -1.11% |
| YTD return | -26.84% | -6.78% |
| 1-year return | -54.83% | -58.53% |
| 5-year return | — | -99.46% |
| EPS (TTM) | $-0.46 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.96 | $4.19 |
| 52-week low | $0.425 | $0.813 |
| Distance from 52-week high | -67.04% | -76.64% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +1330.32% |
| Average volume | 5.35M | 581.98K |
| Shares outstanding | 18.54M | 11.62M |
| Employees | 9 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bullfrog AI
BFRG stock →Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Phio Pharmaceuticals
PHIO stock →Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
BFRG vs PHIO FAQ
Which is bigger, Bullfrog AI or Phio Pharmaceuticals?
Bullfrog AI (BFRG) is larger, with a market capitalization of $11.98M compared with $11.37M for Phio Pharmaceuticals (PHIO).
Which stock has performed better over the past year, BFRG or PHIO?
BFRG returned -54.83% over the past 12 months, compared with -58.53% for PHIO (price return, excluding dividends). Past performance does not predict future results.
Are Bullfrog AI and Phio Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.